Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid in NAFLD with Raised ALT
NCT03836937Completed
- Sponsor
- Sir Salimullah Medical College and Mitford Hospital
- Start
- Mar 2019
- Primary completion
- Nov 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of obeticholic acid in non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Sir Salimullah Medical College and Mitford Hospital. Primary endpoints: Change in fibroscan score at 12 weeks, Change in CAP value at 12 weeks and 13 more. Started Mar 2019; status: completed.
02
Drugs
obeticholic acid
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03836937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03836937.